Related Experiment Videos
Sulfasalazine-induced fulminant hepatic failure
G Marinos1, J Riley, D M Painter
1A.W. Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Camperdown, Australia.
Journal of Clinical Gastroenterology
|March 1, 1992
Summary
Sulfasalazine can cause severe liver damage (massive hepatic necrosis) in patients with inflammatory bowel disease. This rare hypersensitivity reaction highlights potential risks associated with this medication.
Area of Science:
- Hepatology
- Gastroenterology
- Immunology
Background:
- Sulfasalazine is a common treatment for inflammatory bowel disease (IBD).
- Drug-induced liver injury is a known, albeit uncommon, adverse effect of various medications.
- Patients with autoimmune conditions may have altered immune responses.
Observation:
- Two patients with IBD developed massive hepatic necrosis after sulfasalazine use.
- Both patients exhibited symptoms of a generalized hypersensitivity reaction.
- One patient had a history of Sjögren's syndrome, an autoimmune disorder.
Findings:
- Sulfasalazine was associated with acute, severe liver failure in these cases.
- Hypersensitivity reactions can manifest as significant hepatic toxicity.
- Outcomes were poor, with one patient dying before transplant and the other succumbing to invasive aspergillosis post-transplant.
Implications:
- Clinicians should be vigilant for sulfasalazine-induced hepatotoxicity, especially in IBD patients.
- Awareness of this severe adverse effect is crucial given the availability of alternative IBD therapies.
- Early recognition and withdrawal of the offending agent may be critical for patient outcomes.